focus -WSS

focus

author：leisure time 2025-09-27 13:09:35 - browse：37

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Websites selling Wegovy, Zepbound ingredients targeted by FDA

focus

WSS

Juul documents reveal insider tactics on political lobbying

Having children helps parents live longer, especially after age 80

Timeline: How the deadly wildfires took over Maui day by day

Schizophrenia gene found to be linked to cells' energy dysfunction

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Timeline: How the deadly wildfires took over Maui day by day

knowledge

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bernie Sanders gets little from pharma CEOs on drug prices

Psychedelics group wrestles with new pharma identity

Juul documents reveal insider tactics on political lobbying

In Memoriam: Notable people who died in 2023

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

After Optum profits sink, UnitedHealth makes changes

Wildfire smoke exposes gaps in outdoor worker protections

Patients, digital health players weigh in on FTC's data privacy plan

explore

Illumina slashes 2023 revenue projections yet again

Long Covid research funding gets a major boost from NIH

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Congress considering partial increase for doctor pay in Medicare

Biden administration begins canceling student loan debt for 804,000 borrowers

Why don't Americans have at

explore

focus

focus

knowledge